Veterinary Medicines

Lamoxsan 150 mg/ml suspension for injection for cattle and pigs

Authorised
  • Amoxicillin
Download as PDF

Product identification

Medicine name:
Lamoxsan 150 mg/ml suspension for injection for cattle and pigs
Lamoxsan 150 mg/ml szuszpenziós injekció szarvarmarhák és sertések részére
Active substance:
  • Amoxicillin
Target species:
  • Cattle
  • Pig
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Amoxicillin
    150.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Meat and offal
        18
        day
      • Milk
        72
        hour
    • Pig
      • Meat and offal
        20
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01CA04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Hungary
Package description:
  • Clear PET vial of 100 ml closed with type I laminated chlorobutyl rubber stopper and aluminium cap in a carton box.
  • Clear PET vial of 250 ml closed with type I laminated chlorobutyl rubber stopper and aluminium cap in a carton box.
  • Clear type II glass vial of 100 ml closed with type I laminated chlorobutyl rubber stopper and aluminium cap in a carton box.
  • Clear type II glass vial of 250 ml closed with type I laminated chlorobutyl rubber stopper and aluminium cap in a carton box.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 18 of Regulation (EU) 2019/6)
Marketing authorisation holder:
  • Alfasan Nederland B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Alfasan Nederland B.V.
Responsible authority:
  • Directorate Of Veterinary Medicinal Products
Authorisation number:
  • 4395/X/23 NÉBIH ÁTI
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0391/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
This information is not available for this product.

Documents

Summary of Product Characteristics

English (PDF)
Published on: 22/08/2023
Download

Package Leaflet and Labelling

English (PDF)
Published on: 22/08/2023
Download

NLV0391001DC_DCP_Lamoxsan final PuAR.pdf

English (PDF)
Published on: 29/02/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."